We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Neuromuscular Stimulator Treats Gait Deficits in MS Patients

By HospiMedica International staff writers
Posted on 07 Apr 2021
Print article
Image: Neuromuscular Stimulator Treats Gait Deficits in MS Patients  (Photo courtesy of Helius Medical)
Image: Neuromuscular Stimulator Treats Gait Deficits in MS Patients (Photo courtesy of Helius Medical)
A novel neuromuscular tongue stimulator provides short-term treatment of gait deficit resulting from multiple sclerosis (MS).

The Portable Neuromodulation Stimulator (PoNS), a product of Helius Medical (HMT; Newtown, PA, USA), is a non-implantable device that delivers mild neuromuscular electrical stimulation to the dorsal surface of the tongue, a process called translingual neurostimulation (TLNS). TLNS stimulates both the trigeminal and facial nerves, creating a flow of neural impulses that are then delivered directly into the brain stem. From there, these impulses activate or reactivate neurons and structures involved in human function--the cortex, spinal cord, and potentially the entire central nervous system.

PoNS consists of a controller and a connected mouthpiece, held lightly in place by the lips and teeth. The controller, draped around the neck during therapy, sends signals to the tongue via the mouthpiece; in turn, receptors on the tongue send millions of neural impulses to the brain through natural pathways. PoNS is intended as a short term treatment (up to 14 weeks) of gait deficit due to mild and moderate MS symptoms, and mild-to-moderate traumatic brain injury (TBI), in conjunction with physical therapy. Therapists can connect view usage data and identify potential areas of missed or shortened sessions.

Multiple sclerosis is an inflammatory disease in which the fatty myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and scarring as well as a broad spectrum of signs and symptoms, such as problems with walking and balance, which interfere with daily activities, but or manageable. The most common walking problem is unsteady, uncoordinated movements (known as ataxia) due to damage to the areas of the brain that coordinate muscle balance.

Related Links:
Helius Medical



Print article

Channels

Business

view channel
Image: Respicardia’s remedē System (Photo courtesy of Respicardia, Inc.)

Zoll Medical Acquires CSA Systems Manufacturer Respicardia

ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has acquired Respicardia, Inc. (Minnetonka, MN, USA), a provider of novel implantable neurostimulators for the treatment of moderate... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.